Exelixis

Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including : The company also has various compounds in phase 1 clinical trials, including Its lead compound, XL184, is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney, and medullary thyroid cancer. XL184 was recently designated orphan drug status by the FDA and given the generic name, cabozantinib. Cabozantinib is an inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to abrogate tumor growth, metastasis, and angiogenesis.